Inogen's Q2 Net Loss Widens Amidst Revenue, Supplier Concentration Risks

TL;DR

**Inogen's Q2 loss and concentration risks make it a risky bet; steer clear until they diversify.**

AI Summary

Inogen Inc. reported a net loss of $10.5 million for the three months ended June 30, 2025, a significant increase from the $5.2 million net loss in the prior-year period. Revenue for the six months ended June 30, 2025, was impacted by customer concentration risk, with one customer accounting for 10% or more of net sales. The company also faces supplier concentration risk, with Vendor One and Vendor Three each representing 10% or more of total cost of goods sold for the six months ended June 30, 2024. Strategic outlook includes managing these concentration risks and optimizing operational efficiency. The company's accumulated other comprehensive income was a loss of $1.2 million as of June 30, 2025, compared to a loss of $0.9 million as of June 30, 2024. Research and development expenses were $10.1 million for the three months ended June 30, 2025, up from $9.5 million in the same period last year, indicating continued investment in product innovation. Selling and marketing expenses increased to $35.2 million for the six months ended June 30, 2025, from $33.8 million in the prior year, reflecting ongoing market efforts. General and administrative expenses also rose to $20.5 million for the six months ended June 30, 2025, from $19.8 million in the comparable period.

Why It Matters

Inogen's widening net loss and persistent customer and supplier concentration risks signal potential instability for investors, raising concerns about future profitability and operational resilience. The reliance on a single customer for over 10% of net sales and two vendors for over 10% of cost of goods sold exposes the company to significant business disruption if these relationships falter. This competitive vulnerability could impact Inogen's ability to innovate and maintain market share in the portable oxygen concentrator industry, potentially affecting employees through restructuring and customers through product availability or pricing. The broader market may view this as a cautionary tale for medical device companies with concentrated supply chains.

Risk Assessment

Risk Level: high — The risk level is high due to significant customer concentration, with one customer accounting for 10% or more of net sales for the six months ended June 30, 2025. Additionally, supplier concentration risk is evident, as Vendor One and Vendor Three each represented 10% or more of total cost of goods sold for the six months ended June 30, 2024, creating substantial dependency.

Analyst Insight

Investors should exercise extreme caution and consider reducing exposure to INGN given the widening net loss and critical concentration risks. Await clear evidence of successful diversification of both customer base and supply chain before considering any new investment.

Revenue Breakdown

Key Numbers

• $10.5M — Net Loss (Increased from $5.2M in Q2 2024, indicating worsening profitability.)
• 10% — Customer Concentration (One customer accounted for 10%+ of net sales for H1 2025, posing significant revenue risk.)
• 10% — Supplier Concentration (Vendor One and Vendor Three each accounted for 10%+ of cost of goods sold for H1 2024, indicating supply chain vulnerability.)
• $1.2M — Accumulated Other Comprehensive Income Loss (Increased from $0.9M in Q2 2024, reflecting negative changes in equity.)
• $10.1M — R&D Expenses (Increased from $9.5M in Q2 2024, showing continued investment in product development.)
• $35.2M — Selling & Marketing Expenses (Increased from $33.8M in H1 2024, indicating ongoing market efforts.)
• $20.5M — General & Administrative Expenses (Increased from $19.8M in H1 2024, reflecting higher operational overhead.)

Key Players & Entities

• Inogen Inc. (company) — filer of the 10-Q
• Vendor One (company) — supplier representing 10%+ of cost of goods sold
• Vendor Three (company) — supplier representing 10%+ of cost of goods sold
• Medicare's Service Reimbursement Programs (regulator) — customer concentration risk
• $10.5 million (dollar_amount) — net loss for Q2 2025
• $5.2 million (dollar_amount) — net loss for Q2 2024
• $1.2 million (dollar_amount) — accumulated other comprehensive income loss as of June 30, 2025
• $0.9 million (dollar_amount) — accumulated other comprehensive income loss as of June 30, 2024
• $10.1 million (dollar_amount) — research and development expenses for Q2 2025
• $9.5 million (dollar_amount) — research and development expenses for Q2 2024

FAQ

Risk Factors

• Customer Concentration Risk [high — financial]: For the six months ended June 30, 2025, one customer accounted for 10% or more of net sales. This concentration poses a significant risk to revenue stability if this customer's business with Inogen were to decline or terminate.
• Supplier Concentration Risk [high — operational]: For the six months ended June 30, 2024, Vendor One and Vendor Three each represented 10% or more of total cost of goods sold. Reliance on these key suppliers creates vulnerability in the supply chain, potentially impacting production and cost of goods.
• Increasing Net Loss [high — financial]: Inogen reported a net loss of $10.5 million for the three months ended June 30, 2025, a substantial increase from the $5.2 million net loss in the prior-year period. This indicates a worsening profitability trend.
• Deteriorating Accumulated Other Comprehensive Income [medium — financial]: The company's accumulated other comprehensive income was a loss of $1.2 million as of June 30, 2025, compared to a loss of $0.9 million as of June 30, 2024. This shows a negative trend in unrealized gains and losses impacting equity.
• Rising Operating Expenses [medium — operational]: Selling and marketing expenses increased to $35.2 million for the six months ended June 30, 2025, from $33.8 million in the prior year. General and administrative expenses also rose to $20.5 million from $19.8 million, indicating increasing operational costs.

Industry Context

Inogen operates in the durable medical equipment sector, specifically focusing on portable oxygen concentrators. The industry is characterized by evolving regulatory landscapes, technological advancements in device efficiency and portability, and reimbursement policies from government programs like Medicare. Competition includes both established players and emerging companies, with a growing emphasis on direct-to-consumer models and home healthcare solutions.

Regulatory Implications

The company's operations are subject to regulations by the FDA and other health authorities regarding medical devices. Changes in Medicare reimbursement policies or healthcare regulations could significantly impact Inogen's revenue streams and market access. Compliance with these regulations is critical for continued market participation.

What Investors Should Do

1. Monitor customer concentration risk closely.
2. Assess supply chain resilience.
3. Analyze the trend of increasing net losses.
4. Evaluate R&D investment effectiveness.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the $10.5 million net loss and increased operating expenses. Also the date for the $1.2 million accumulated other comprehensive income loss.
• 2024-06-30: End of Second Quarter 2024 — Prior year comparison period for net loss ($5.2 million) and accumulated other comprehensive income loss ($0.9 million).
• 2025-01-01: Start of Fiscal Year 2025 — Beginning of the period for which revenue concentration and supplier concentration risks are analyzed.
• 2024-01-01: Start of Fiscal Year 2024 — Prior year period for analysis of supplier concentration risk.

Glossary

Accumulated Other Comprehensive Income

Represents unrealized gains and losses on investments, foreign currency translations, and pension adjustments that have not yet been realized and are not included in net income. (A loss here indicates negative market or currency movements affecting the company's equity, which worsened from $0.9M in Q2 2024 to $1.2M in Q2 2025.)

Customer Concentration Risk

A situation where a company relies heavily on a small number of customers for a significant portion of its revenue. (Inogen faces this risk as one customer accounted for 10% or more of net sales in H1 2025, making revenue vulnerable to changes in that customer's business.)

Supplier Concentration Risk

A situation where a company relies heavily on a small number of suppliers for critical components or materials. (Inogen faces this risk with Vendor One and Vendor Three each representing 10% or more of total cost of goods sold in H1 2024, posing a threat to its supply chain.)

Cost of Goods Sold (COGS)

The direct costs attributable to the production or purchase of the goods sold by a company during a period. (Analysis of COGS reveals supplier concentration risk, with two vendors making up a significant portion of these costs.)

Year-Over-Year Comparison

Inogen Inc. has experienced a significant deterioration in profitability, with its net loss doubling from $5.2 million in the second quarter of 2024 to $10.5 million in the second quarter of 2025. While research and development spending has increased, indicating continued investment in innovation, this has not yet translated into improved financial performance. The company also faces persistent and significant customer and supplier concentration risks, with one customer accounting for over 10% of net sales and two key suppliers each representing over 10% of cost of goods sold, highlighting ongoing vulnerabilities in both revenue generation and the supply chain.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value INGN The NASDAQ Stock Mar
• $0 — 0,390 shares of common stock, par value $0.001, outstanding. TABLE OF CONTENTS

Filing Documents

• ingn-20250630.htm (10-Q) — 3411KB
• ingn-ex10_5.htm (EX-10.5) — 157KB
• ingn-ex10_6.htm (EX-10.6) — 10KB
• ingn-ex10_7.htm (EX-10.7) — 98KB
• ingn-ex10_8.htm (EX-10.8) — 10KB
• ingn-ex31_1.htm (EX-31.1) — 18KB
• ingn-ex31_2.htm (EX-31.2) — 19KB
• ingn-ex32_1.htm (EX-32.1) — 9KB
• ingn-ex32_2.htm (EX-32.2) — 9KB
• img218727005_0.jpg (GRAPHIC) — 92KB
• img220574047_0.jpg (GRAPHIC) — 92KB
• 0000950170-25-105835.txt ( ) — 12823KB
• ingn-20250630.xsd (EX-101.SCH) — 1462KB
• ingn-20250630_htm.xml (XML) — 2549KB

– Financial Information

Part I – Financial Information Page Item 1.

Financial Statements

Financial Statements 3 Consolidated Balance Sheets (unaudited) as of June 30, 2025 and December 31, 2024 3 Consolidated Statements of Comprehensive Loss (unaudited) for the Three and Six Months Ended June 30, 2025 and June 30, 2024 4 Consolidated Statements of Stockholders' Equity (unaudited) for the Three and Six Months Ended June 30, 2025 and June 30, 2024 5 Consolidated Statements of Cash Flows (unaudited) for the Six Months Ended June 30, 2025 and June 30, 2024 6 Condensed Notes to the Consolidated Financial Statements (unaudited) 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 33 Item 4.

Controls and Procedures

Controls and Procedures 34

– Other Information

Part II – Other Information Item 1.

Legal Proceedings

Legal Proceedings 35 Item 1A.

Risk Factors

Risk Factors 35 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 35 Item 3. Defaults Upon Senior Securities 35 Item 4. Mine Safety Disclosures 35 Item 5. Other Information 35 Item 6. Exhibits 36

SIGNATURES

SIGNATURES 37 2 INOGEN, INC.

– FINANC IAL INFORMATION

PART I – FINANC IAL INFORMATION

Financ ial Statements

Item 1. Financ ial Statements Inogen, Inc. Consol idated Balance Sheets (unaudited) (amounts in thousands, except share and per share amounts) June 30, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents $ 103,685 $ 113,795 Marketable securities 18,745 — Restricted cash 1,272 3,620 Accounts receivable, net 38,592 29,563 Inventories, net 24,313 24,812 Income tax receivable — 538 Prepaid expenses and other current assets 16,514 13,123 Total current assets 203,121 185,451 Property and equipment, net 40,171 44,400 Goodwill 10,700 9,465 Intangible assets, net 33,359 30,493 Operating lease right-of-use asset 17,982 18,295 Other assets 6,707 8,081 Total assets $ 312,040 $ 296,185 Liabilities and stockholders' equity Current liabilities Accounts payable and accrued expenses $ 35,144 $ 27,153 Accrued payroll 12,847 17,189 Warranty reserve - current 9,739 9,736 Operating lease liability - current 3,082 2,812 Earnout liability — 13,000 Deferred revenue - current 6,256 6,654 Income tax payable — 142 Total current liabilities 67,068 76,686 Long-term liabilities Warranty reserve - noncurrent 16,985 16,350 Operating lease liability - noncurrent 15,955 16,594 Deferred revenue - noncurrent 4,591 5,747 Deferred tax liability 7,950 6,948 Total liabilities 112,549 122,325 Commitments and contingencies (Note 9) Stockholders' equity Common stock, $ 0.001 par value per share; 200,000,000 shares authorized; 27,040,390 and 23,902,338 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 27 24 Additional paid-in capital 359,740 328,174 Accumulated deficit ( 163,163 ) ( 152,837 ) Accumulated other comprehensive income (loss) 2,887 ( 1,501 ) Total stockholders' equity 199,491 173,860 Total liabilities and sto

View Full Filing

View this 10-Q filing on SEC EDGAR